Can-Fite BioPharma
AboutSciencePipelineInvestor InformationContact Us
About Can-Fite BioPharmaAbout Can-Fite BioPharmaAbout Can-Fite BioPharmaAbout Can-Fite BioPharma

Can-Fite BioPharma (TASE:CFBI; NYSE MKT:CANF) is an Israeli biopharmaceutical company with fully integrated pharmaceutical discovery and clinical development capabilities. The company has an advanced pipeline of proprietary compounds in phase 2 and 3 clinical development stage, which address autoimmune-inflammatory and cancer diseases.


The company technology platform is based on the finding that the Gi protein coupled A3 adenosine receptor (A3AR) is highly expressed in inflammatory and cancer cells whereas low expression is found in normal body cells. High A3AR expression levels are also >>  more...


Can-Fite has a number of drugs in various stages of research and development. The pipeline drugs are synthetic, highly specific agonists and an allosteric modulator, all target the A3 adenosine receptor. All drugs are orally bioavailable with an excellent >> more...


February 6, 2013
Can Fite Submitted Phase II Study Protocol with CF102  to Treat Patients with Advanced Liver Cancer
>> more...
Devember 23, 2013
Can-Fite BioPharma Announces Top-Line Results of Phase IIb Study with CF101 as a Monotherapy for Rheumatoid Arthritis
>> more...